Safety evaluation of GUMBOKAL IM FORTE SPF live intermediate vaccine against infectious bursal disease (CROSBI ID 110468)
Prilog u časopisu | izvorni znanstveni rad
Podaci o odgovornosti
Savić, Gordana ; Ćurić, Stipica ; Savić, Vladimir
engleski
Safety evaluation of GUMBOKAL IM FORTE SPF live intermediate vaccine against infectious bursal disease
Safety of GUMBOKAL IM FORTE SPF, live infectious bursal disease vaccine, was evaluated in compliance with European Pharmacopoeia. Ten-fold dose (10 to power 5.0 TCID 50 per chicken) of the vaccine was given to one-day-old as well as 15-day-old specific pathogen free chickens by ocular route. Chickens were observed daily for following 21 days when they were killed and bursas were submitted for histological examination. No clinical signs or mortality were recorded during the observation period in both groups. In bursas of most of the birds vaccinated in age of one day, intermediate atrophy and mild inflammation and fibrosis were found. These alterations were manifesting in 50% lymphocyte depletion with intermediate vacuolisation in approximately 50% of lymphoid follicles, whereas in other lymphoid follicles only mild lymphoid depletion and mild vacuolisation were noted. In bursas of the chickens vaccinated in age of 15 days no atrophy of epithelium was found, but mild to moderate lymphoid depletion and/or vacuolisation of lymphoid follicles were noted. However, lymphoid follicles in these birds were regularly shaped as well as interstitial conjunctive tissue. The results in both groups indicate not only mild to intermediate alterations of the bursas, but also tendency of their recovery and B cell repopulation. Although GUMBOKAL IM FORTE SPF did not fully comply European Pharmacopoeia requirements, it can be considered to be safe live infectious bursal disease vaccine of intermediary type.
infectious bursal disease; live vaccine; safety
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano